On May 1, the U.S. Food and Drug Administration approved CAR-T cell therapy developed by Penn Medicine for use in the most common form of non-Hodgkin’s lymphoma. This breakthrough means that more patients will be able to receive the potentially life-saving treatment.Click here to read more.
Staff at the Ann B. Barshinger Cancer Institute gathered May 2 to celebrate a second FDA approval of the Penn Medicine-developed CAR-T cell therapy, this time for adult patients with non-Hodgkin’s lymphoma.
Find our contact forms and phone numbers or give feedback on a recent experience using Care to Share.
View test results, schedule appointments, or request prescription refills from the convenience of your computer or mobile device.
Learn about health system news and meet new providers in Progress Notes, Lancaster General Health's provider newsletter.